Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vebonin (triptorelin)
- Development stage
- Approved
- Lead developer
- Chengdu Tiantaishan Pharmaceutical
- Modality
- Peptides
- Administration
- Intramuscular
01
Overview
Vebonin is a brand name for a sustained-release microsphere formulation of triptorelin acetate, a synthetic decapeptide agonist of the gonadotropin-releasing hormone (GnRH) receptor. As a potent GnRH analogue, triptorelin initially stimulates the pituitary gland to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). However, continuous administration via the microsphere delivery system leads to the down-regulation of GnRH receptors and desensitization of pituitary gonadotropes. This results in a profound suppression of gonadotropin secretion and a subsequent reduction in sex steroid levels to castrate or postmenopausal levels. In the context of assisted reproductive technology (ART), Vebonin is utilized in long GnRH agonist protocols to prevent premature LH surges during controlled ovarian hyperstimulation. It is also indicated for the treatment of hormone-dependent conditions such as advanced prostate cancer, endometriosis, and uterine fibroids. The drug is manufactured by Chengdu Tiantai Pharmaceutical in China.
- Brand names
- VeboninWeibaoning
- Other names
- triptorelin acetateTriptorelin Acetate Microspheres for Injection
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on Vebonin (triptorelin).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vebonin (triptorelin).